Tag archive for ‘APF530’
A.P. Pharma: Ondansetron’s Link to QT Interval Prolongation is a Huge Positive for APF530
The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to QT interval prolongation; this condition can cause abnormal heart rhythms that in some cases may be life threatening. This follows a previous communication on the same concern on September 11, 2011. Because AP Pharma’s competitive […]